Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Diabetes Care

• Publication date

  2017-12-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.2337/dc17-0417PMID 29246950
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.

  2016cited by this paper
• CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM--2016 EXECUTIVE SUMMARY.

  2016cited by this paper
• Association Between Incretin-Based Drugs and the Risk of Acute Pancreatitis.

  2016cited by this paper
• Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide.

  2015cited by this paper
• Systematic Literature Review and Meta-analysis of Medication Adherence With Once-weekly Versus Once-daily Therapy.

  2015cited by this paper
• Exenatide once weekly versus insulin glargine for type 2 diabetes (DURATION-3): 3-year results of an open-label randomised trial.

  2014cited by this paper
• Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes

  2014cited by this paper
• Glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes: differences and similarities.

  2014cited by this paper
• HARMONY 3: 104-Week Randomized, Double-Blind, Placebo- and Active-Controlled Trial Assessing the Efficacy and Safety of Albiglutide Compared With Placebo, Sitagliptin, and Glimepiride in Patients With Type 2 Diabetes Taking Metformin

  2014cited by this paper
• The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss.

  2014cited by this paper
• Efficacy and Safety of Dulaglutide Added Onto Pioglitazone and Metformin Versus Exenatide in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-1)

  2014cited by this paper
• Exenatide Twice Daily: A Review of Its Use in the Management of Patients with Type 2 Diabetes Mellitus

  2014cited by this paper
• Erratum. Efficacy and Safety of Dulaglutide Added Onto Pioglitazone and Metformin Versus Exenatide in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-1). Diabetes Care 2014;37:2159–2167

  2014influential reference
• Marked Expansion of Exocrine and Endocrine Pancreas With Incretin Therapy in Humans With Increased Exocrine Pancreas Dysplasia and the Potential for Glucagon-Producing Neuroendocrine Tumors

  2013cited by this paper
• Hypoglycemia and Diabetes: A Report of a Workgroup of the American Diabetes Association and The Endocrine Society

  2013cited by this paper
• Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study.

  2013cited by this paper
• GLP-1 receptor activated insulin secretion from pancreatic β-cells: mechanism and glucose dependence

  2012cited by this paper
• Efficacy and Safety of Exenatide Once Weekly Versus Metformin, Pioglitazone, and Sitagliptin Used as Monotherapy in Drug-Naive Patients With Type 2 Diabetes (DURATION-4)

  2012cited by this paper
• Exenatide Extended-Release

  2012cited by this paper
• Patient perspectives on once‐weekly medications for diabetes

  2011cited by this paper
• DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes.

  2011cited by this paper
• Bene fi ts of ModestWeight Loss in Improving Cardiovascular Risk Factors in Overweight and Obese Individuals With Type 2 Diabetes

  2011cited by this paper
• Benefits of Modest Weight Loss in Improving Cardiovascular Risk Factors in Overweight and Obese Individuals With Type 2 Diabetes

  2011cited by this paper
• Tipping the balance: the pathophysiology of obesity and type 2 diabetes mellitus.

  2011cited by this paper
• Article: Treatment

  2010cited by this paper
• DURATION-1: Exenatide Once Weekly Produces Sustained Glycemic Control and Weight Loss Over 52 Weeks

  2010cited by this paper
• The Impact of Weight Gain on Motivation, Compliance, and Metabolic Control in Patients with Type 2 Diabetes Mellitus

  2009cited by this paper
• Liraglutide: a once-daily GLP-1 analogue for the treatment of Type 2 diabetes mellitus

  2007cited by this paper
• Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.

  1998cited by this paper
• Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.

  1998cited by this paper
• Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)

  1998cited by this paper
• rapid communication Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2

  year unknowncited by this paper

• Once-Monthly and Extended-Interval Incretin-, Amylin-, and THRβ-Targeting Therapies for Type 2 Diabetes and Obesity: Clinical Evidence and Development Pipelines

  2026cites this paper
• Evaluation of the effectiveness of semaglutide in providing metabolic control and correction of insulin resistance in patients with type 2 diabetes mellitus in real clinical practice

  2026cites this paper
• Semaglutide Use Is Associated With Decreased Length of Stay and Hospital Costs in Patients Undergoing Anterior Lumbar Interbody Fusion: A Retrospective Cohort Study.

  2026cites this paper
• The Effect of GLP-1 Receptor Agonist and SGLT2 Inhibitor on Infection Risk: Network Meta-Analysis.

  2026cites this paper
• Exploring the rates of Gastrointestinal adverse effects among five GLP-1 receptor agonists: A systematic review and Meta-Analysis of randomized controlled trials

  2026cites this paper
• The Role of Glucagon-Like Peptide-1 Receptor Agonists in the Treatment of Cardiovascular-Kidney-Metabolic Syndrome

  2026cites this paper
• Advances in GLP-1 receptor agonists delivery systems for obesity and diabetes

  2026cites this paper
• Neuroprotective effects of semaglutide targeting the left temporal lobe in adults with overweight or obesity: A 24-week multimodal neuroimaging study.

  2026cites this paper
• Agent- and Dose-Specific Intestinal Obstruction Safety of GLP-1 Receptor Agonists and SGLT2 Inhibitors: A Network Meta-Analysis of Randomized Trials

  2026cites this paper
• Metabolic Outcomes in Patients With Type 2 Diabetes Prescribed Incretin‐Based Therapy and Referred or Not to a Weight Management Clinic: A Single‐Center Retrospective Analyses

  2026cites this paper
• Advances in incretin therapies for targeting cardiovascular disease in diabetes.

  2025cites this paper
• GLP-1 receptor agonists, are we witnessing the emergence of a paradigm shift for neuro-cardio-metabolic disorders?

  2025cites this paper
• Glucagon-Like Peptide-1 Agonist Use in Adults With Congenital Heart Disease

  2025cites this paper
• Semaglutide in Diabetic Kidney Disease: Integrating Clinical Evidence with Mechanistic Insights

  2025cites this paper
• Type 2 Diabetes Mellitus: New Pathogenetic Mechanisms, Treatment and the Most Important Complications

  2025cites this paper
• Drug adherence, glycemic control, and weight reduction with subcutaneous semaglutide in real-world management of type 2 diabetes.

  2025cites this paper
• Long-term comparative effectiveness of once-weekly semaglutide versus alternative treatments in a real-world US adult population with type 2 diabetes: a randomized pragmatic clinical trial

  2025cites this paper
• Semaglutide: Multilevel organ protection in type 2 diabetes – from the heart and kidneys to peripheral vessels

  2025cites this paper
• The Art and Science of Antidiabetic Medications and Obesity Management.

  2025cites this paper
• Examining the Omission of Dietary Quality Data in Glucagon-Like Peptide 1 Clinical Trials: A Scoping Review

  2025cites this paper
• Effectiveness and Safety of Once-Weekly Semaglutide in Japanese Patients with Type 2 Diabetes: A Retrospective Observational Multicenter Study (ORIGAMI Study)

  2025cites this paper
• Systematic review and synthesis without meta-analysis (SWiM) reveals lack of clinical studies and weak preclinical evidence for interaction between glucose regulating drugs and environmental contaminant exposure.

  2025cites this paper
• Use of glucagon-like peptide-1 receptor agonists and incretin mimetics for type 2 diabetes and obesity: A narrative review.

  2025cites this paper
• Newer GLP-1 RAs Are Associated With Improved Glycemic Control in US Adults With Type 2 Diabetes: a Population-Level Time Series Analysis.

  2025cites this paper
• Sind GLP-1-Rezeptor-Agonisten und SGLT2-Inhibitoren auch im höheren Lebensalter geeignet?

  2025cites this paper
• The pleiotropic effects of glucagon-like peptide-1 receptor agonists in patients with metabolic dysfunction-associated steatohepatitis: a review for gastroenterologists

  2025cites this paper
• Translating Guidelines into Practice: A Prospective Real-World Study of a Romanian Cohort Treated with GLP-1 RAs

  2025cites this paper
• GLP-1 Receptor Signaling and Oral Dysfunction: A Narrative Review on the Mechanistic Basis of Semaglutide-Related Oral Adverse Effects

  2025cites this paper
• Semaglutide use before single-level lumbar fusion associated with fewer readmissions and 90-day costs

  2025cites this paper
• The potential role of GLP-1 receptor agonists in the management of psoriatic disease: a scoping review

  2025cites this paper
• Efficacy and safety of different once-weekly glucagon-like peptide-1 receptor agonists—A systematic review and Bayesian network meta-analysis

  2025cites this paper
• The expanding role of semaglutide: beyond glycemic control

  2025cites this paper
• Meta-analysis of the Effect of Semaglutide on Blood Pressure in Obese Populations

  2025cites this paper
• Once-weekly IcoSema versus multiple daily insulin injections in type 2 diabetes management (COMBINE 3): an open-label, multicentre, treat-to-target, non-inferiority, randomised, phase 3a trial.

  2025cites this paper
• GLP-1 agonists in glycemic and weight control of type 2 diabetes. New perspectives.

  2025cites this paper
• The Association Between Glucagon-Like Peptide-1 Receptor Agonists and Postoperative Complications After Arthroplasty: A Systematic Review and Meta-Analysis.

  2025cites this paper
• Sind GLP-1-Rezeptor-Agonisten und SGLT2-Inhibitoren auch im höheren Lebensalter geeignet?

  2025cites this paper
• The Impact of Semaglutide on Metabolic Syndrome: A Case Report

  2025cites this paper
• Real-World Treatment Patterns Among US Patients With Type 2 Diabetes Mellitus Initiating Treatment With Once Weekly Semaglutide for Diabetes.

  2025cites this paper
• Drug depots for obesity targeting metabolism, appetite, and inflammation

  2025influential citation
• An updated patent review of small molecule glucagon receptor antagonists (2020–2024)

  2025influential citation
• GLP-1 Receptor Agonists as a Novel Solution for Antipsychotic-Induced Weight Gain in Severe and Persistent Mental Illness.

  2025cites this paper
• Once-weekly IcoSema versus once-weekly semaglutide in adults with type 2 diabetes: the COMBINE 2 randomised clinical trial

  2025cites this paper
• The impact of semaglutide on liver outcomes in patients with or at risk of MASH: a dose and duration response meta-analysis of randomized trials

  2025cites this paper
• The gynecologic tumor risk related to GLP-1 receptor agonists and SGLT2 inhibitors use: a network meta-analysis of 91 randomized controlled trials

  2025cites this paper
• The Effect of Semaglutide on Pancreatic β-Cell Function in Adults with Type 2 Diabetes: A Systematic Review and Meta-Analysis

  2025cites this paper
• Comparing the Efficacy of Liraglutide and Semaglutide on Weight Loss: Experience from the Middle East Gulf Region and Literature Review

  2025cites this paper
• Once-Weekly Semaglutide Versus Sodium-Glucose Co-transporter 2 Inhibitors: Real-World Impact on Weight, HbA1c, and Healthcare Resource Utilization in Type 2 Diabetes (PAUSE)

  2025cites this paper
• The agony and the efficacy: central mechanisms of GLP-1 induced adverse events and their mitigation by GIP

  2025cites this paper
• Comparison of the efficacy and safety of GLP‐1 receptor agonists on cardiovascular events and risk factors: A review and network meta‐analysis

  2025cites this paper
• Evolving role of double and triple therapy with GLP-1 receptor agonists in obesity and cardiovascular disease.

  2025cites this paper
• GLP-1R in diabetes mellitus: from basic discovery to therapeutics development

  2025cites this paper
• Efficacy and Safety of Tirzepatide Compared with GLP-1 RAs in Patients with Type 2 Diabetes Treated with Basal Insulin: A Network Meta-analysis

  2025cites this paper
• The promise of incretin-based pharmacotherapies for metabolic dysfunction-associated fatty liver disease

  2025cites this paper
• New advances in novel pharmacotherapeutic candidates for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) between 2022 and 2024

  2025cites this paper
• Novel Antidiabetic Drugs and Risk of Venous Thromboembolism: A Literature Review

  2025cites this paper
• Effect of Weight‐Neutral Treatment With Semaglutide or Tirzepatide on β‐Cell Identity in db/db Mice

  2025cites this paper
• 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2026.

  2025cites this paper
• Semaglutide as a GLP-1 Agonist: A Breakthrough in Obesity Treatment

  2025cites this paper
• Valoración en vida real de la eficacia y de la seguridad del cambio de dulaglutida semanal a semaglutida semanal: estudio SEMA-SWITCH

  2025cites this paper
• Exploring Beyond Numeric Weight Loss: The Metabolic Effects of Semaglutide.

  2025cites this paper
• Semaglutide sustained-release microspheres with single-phase zero-order release behavior: effects of polymer blending and surfactants

  2025cites this paper
• Treat metabolic diseases with effective and approved therapies while new treatments are under investigation

  2025cites this paper
• Real-world evaluation of the efficacy and safety of switching from weekly dulaglutide to weekly semaglutide: The SEMA-SWITCH study.

  2025cites this paper
• The pharmacodynamics-based prophylactic benefits of GLP-1 receptor agonists and SGLT2 inhibitors on neurodegenerative diseases: evidence from a network meta-analysis

  2025cites this paper
• Dual and Triple Gut Peptide Agonists on the Horizon for the Treatment of Type 2 Diabetes and Obesity. An Overview of Preclinical and Clinical Data

  2025cites this paper
• High-Dose Semaglutide (Up to 16 mg) in People With Type 2 Diabetes and Overweight or Obesity: A Randomized, Placebo-Controlled, Phase 2 Trial

  2025cites this paper
• Reduction of New Onset of Atrial Fibrillation in Patients Treated with Semaglutide: An updated systematic review and meta regression analysis of randomized controlled trials.

  2025cites this paper
• Association of Glucagon-like Peptide-1 Receptor Agonists with Optic Nerve and Retinal Adverse Events: A Population-Based Observational Study Across 180 Countries.

  2025cites this paper
• Risk of Hearing Loss in Patients Treated with Exendin-4 Derivatives: A Network Meta-Analysis of Glucagon-like Peptide-1 Receptor Agonists and Sodium–Glucose Cotransporter 2 Inhibitors

  2025cites this paper
• Semaglutide: a key medication for managing cardiovascular-kidney-metabolic syndrome

  2025influential citation
• Biased agonism of GLP-1R and GIPR enhances glucose lowering and weight loss, with dual GLP-1R/GIPR biased agonism yielding greater efficacy

  2025cites this paper
• Once‑weekly IcoSema versus once‑weekly insulin icodec in type 2 diabetes management (COMBINE 1): an open‑label, multicentre, treat‑to‑target, randomised, phase 3a trial.

  2025cites this paper
• Research Progress on bioactive peptides from animal sources: A comprehensive review.

  2025cites this paper
• Efficacy and safety of danuglipron (PF‐06882961) in adults with obesity: A randomized, placebo‐controlled, dose‐ranging phase 2b study

  2025cites this paper
• Sind GLP-1-Rezeptor-Agonisten und SGLT2-Inhibitoren auch im höheren Lebensalter geeignet?

  2025cites this paper
• New generation agents for glycemic control and diabetic retinopathy progression: what we need to know?

  2025cites this paper
• GLP-1 and Its Role in Glycogen Production: A Narrative Review

  2025cites this paper
• Efficacy and safety of GLP-1 agonists in the treatment of T2DM: A systematic review and network meta-analysis

  2025cites this paper
• Ocular Adverse Events With Semaglutide: A Systematic Review and Meta-Analysis.

  2025cites this paper
• The Preventive Effects of GLP-1 Receptor Agonists and SGLT2 Inhibitors on Cancer Metastasis: A Network Meta-Analysis of 67 Randomized Controlled Trials

  2025cites this paper
• Effect of semaglutide on arrhythmic, major cardiovascular, and microvascular outcomes in patients with type 2 diabetes: a systematic review and meta-analysis

  2025cites this paper
• Unraveling the safety profile of GLP-1 receptor agonists: Mechanistic insights with a focus on semaglutide.

  2025cites this paper
• American Association of Clinical Endocrinology Consensus Statement: Algorithm for the Evaluation and Treatment of Adults with Obesity/Adiposity-Based Chronic Disease - 2025 Update.

  2025cites this paper
• Comparative gastrointestinal adverse effects of GLP-1 receptor agonists and multi-target analogs in type 2 diabetes: a Bayesian network meta-analysis

  2025cites this paper
• Glucagon-like peptide-1 increases heart rate by a direct action on the sinus node

  2024cites this paper
• Semaglutide in the Treatment of Diabetes and Associated Obesity

  2024cites this paper
• Lipid profile changes induced by glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a systematic review and network meta-analysis

  2024cites this paper
• Efficacy and Safety of Semaglutide in Weight Loss of Non-diabetic People.

  2024cites this paper
• The effect of GLP-1R agonists on the medical triad of obesity, diabetes, and cancer

  2024cites this paper
• A phase 1, randomized, double‐blind, placebo‐controlled trial investigating the pharmacokinetics, pharmacodynamics, safety and tolerability of oral semaglutide in healthy Chinese subjects

  2024cites this paper
• Porous silicon and silica carriers for delivery of peptide therapeutics

  2024cites this paper
• Gastrointestinal safety evaluation of semaglutide for the treatment of type 2 diabetes mellitus: A meta-analysis

  2024cites this paper
• Newer Outpatient Diabetes Therapies and Technologies.

  2024cites this paper
• Semaglutide in Cardiometabolic Diseases: SELECTing the Target Population

  2024influential citation
• Thyroid Hyperplasia and Neoplasm Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists in the Food and Drug Administration Adverse Event Reporting System: Retrospective Analysis

  2024cites this paper
• Effectiveness and safety of GLP-1 agonist in obese patients with inflammatory bowel disease.

  2024cites this paper
• Switching to tirzepatide 5 mg from GLP-1 RAs: Clinical expectations in the first 12 weeks of treatment.

  2024cites this paper
• Real-world use of oral versus subcutaneous semaglutide in a cohort of type 2 diabetic patients: which option to which patient?

  2024cites this paper
• Assessing glycemic and weight-lowering potential of oral semaglutide in type 2 diabetes compared to other GLP-1 receptor agonists in Indian context

  2024cites this paper